Home/Filings/4/0000950170-25-079926
4//SEC Filing

Milligan Michael Lee 4

Accession 0000950170-25-079926

CIK 0001885522other

Filed

May 29, 8:00 PM ET

Accepted

May 30, 6:31 PM ET

Size

26.2 KB

Accession

0000950170-25-079926

Insider Transaction Report

Form 4
Period: 2025-05-28
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-05-2841,2500 total
    Exercise: $1.69Exp: 2034-02-14Common Stock (41,250 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-05-28+400,000400,000 total
    Exercise: $0.72Exp: 2035-02-13Common Stock (400,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-05-2885,3910 total
    Exercise: $1.69Exp: 2032-01-27Common Stock (85,391 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-05-2838,2340 total
    Exercise: $1.69Exp: 2033-02-17Common Stock (38,234 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-05-2828,6750 total
    Exercise: $1.69Exp: 2033-06-23Common Stock (28,675 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-05-28+38,23438,234 total
    Exercise: $0.72Exp: 2033-02-17Common Stock (38,234 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-05-28+28,67528,675 total
    Exercise: $0.72Exp: 2033-06-23Common Stock (28,675 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-05-28+41,25041,250 total
    Exercise: $0.72Exp: 2034-02-14Common Stock (41,250 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2025-05-28400,0000 total
    Exercise: $1.69Exp: 2035-02-13Common Stock (400,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2025-05-28+85,39185,391 total
    Exercise: $0.72Exp: 2032-01-27Common Stock (85,391 underlying)
Footnotes (7)
  • [F1]25% of the shares subject to the option vest on the first anniversary measured from December 20, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  • [F2]On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 7, all other terms of the option remain unchanged.
  • [F3]25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  • [F4]25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  • [F5]25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  • [F6]25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  • [F7]On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Documents

1 file

Issuer

Neumora Therapeutics, Inc.

CIK 0001885522

Entity typeother

Related Parties

1
  • filerCIK 0001993953

Filing Metadata

Form type
4
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:31 PM ET
Size
26.2 KB